Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Posters by Title

Type your Poster Title, then hit apply

Showing 1,267 results.

Thumbnail for Hematologic Malignancy Diagnosed During Pregnancy: A Single-Center Retrospective Series

AML - 1273

Hematologic Malignancy Diagnosed During Pregnancy: A Single-Center Retrospective Series

Arya Bolla

Poster Presenter: Arya Bolla

Thumbnail for Hematologic Manifestations and Clonal Hematopoiesis in Telomere Biology Disorders: A Retrospective Single-Center Cohort Study

MDS - 565

Hematologic Manifestations and Clonal Hematopoiesis in Telomere Biology Disorders: A Retrospective Single-Center Cohort Study

Olisaemeka Ogbue

Poster Presenter: Olisaemeka Ogbue

Previous 1...57 58 59 60 61 62 63...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Hematologic Toxicity and Treatment Discontinuation With Venetoclax-Based Regimens in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis of Randomized Trials

CLL - 1272

Hematologic Toxicity and Treatment Discontinuation With Venetoclax-Based Regimens in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis of Randomized Trials

Rishi Nanda

Poster Presenter: Rishi Nanda

MPN - 1106

Hematological Profile in Nonhuman Primates of Epetraborole, a Novel Boron-Containing Candidate for Oral Treatment of Polycythemia Vera

Sanjay Chanda

Poster Presenter: Sanjay Chanda

Thumbnail for Hematopoietic Stem Cell Transplantation Activity in the Eastern Mediterranean Region from 2018-2022: An Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group Report.

CT - 1719

Hematopoietic Stem Cell Transplantation Activity in the Eastern Mediterranean Region from 2018-2022: An Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group Report.

Ibrahim Muhsen

Poster Presenter: Ibrahim Muhsen

$Thumbnail for Hematopoietic Stem Cell Transplantation in Infantile Osteopetrosis: Lessons from a resource-limited setting. Background: Infantile Osteopetrosis is a rare inherited bone disorder characterised by a reduced or complete lack of osteoclast function, leading to defective bone resorption and increased bone density. The defective osteoclast differentiation or function is of hemopoietic origin, thus making Hematopoietic stem cell transplantation (HSCT) the only curative treatment option for this condition. Objective: To determine the outcome of HSCT in Infantile Osteopetrosis patients in a low and middle-income country. Methods:This retrospective study analysed the data of 10 cases of infantile osteopetrosis at AFBMTC from April 2016 to December 2024. Cases having fully HLA-matched HSCT were included in the study. All patients received myeloablative conditioning with fludarabine and Busulfan. Genetic mutation analysis was available in only three cases (2 had TCIRG1 and 1 case had RANK mutation). Results:Among the cohort, 6(60%) were male with a mean age of 16.09 + 14.39 months at the time of HSCT Bone marrow harvest was the source of stem cells in all cases except one. Cyclosporine-induced hypertension was the most common complication documented in 100% of cases, followed by Neutropenic fever in 9(90%) cases, mucositis in 6(60%) cases, and VOD in 3 cases (30%). Acute GVHD was documented in 3 (30%) cases, while chronic GVHD was documented in 2(20%). Only one case had post-HSCT hypercalcemia. Mixed Chimerism was observed in 8 cases (80%) in the first 100 days, but did not affect transplant outcomes. OS and DFS for the study were 80%. The cause of death was refractory seizures in one patient, while another patient died due to gut GVHD and septicemia. Conclusion: HSCT is the only curative treatment option that improves the clinical manifestation of infantile osteopetrosis. HSCT at an early age in infantile osteopetrosis can lead to a better quality of life in this potentially fatal disease.$

CT - 622

Hematopoietic Stem Cell Transplantation in Infantile Osteopetrosis: Lessons from a resource-limited setting. Background: Infantile Osteopetrosis is a rare inherited bone disorder characterised by a reduced or complete lack of osteoclast function, leading to defective bone resorption and increased bone density. The defective osteoclast differentiation or function is of hemopoietic origin, thus making Hematopoietic stem cell transplantation (HSCT) the only curative treatment option for this condition. Objective: To determine the outcome of HSCT in Infantile Osteopetrosis patients in a low and middle-income country. Methods:This retrospective study analysed the data of 10 cases of infantile osteopetrosis at AFBMTC from April 2016 to December 2024. Cases having fully HLA-matched HSCT were included in the study. All patients received myeloablative conditioning with fludarabine and Busulfan. Genetic mutation analysis was available in only three cases (2 had TCIRG1 and 1 case had RANK mutation). Results:Among the cohort, 6(60%) were male with a mean age of 16.09 + 14.39 months at the time of HSCT Bone marrow harvest was the source of stem cells in all cases except one. Cyclosporine-induced hypertension was the most common complication documented in 100% of cases, followed by Neutropenic fever in 9(90%) cases, mucositis in 6(60%) cases, and VOD in 3 cases (30%). Acute GVHD was documented in 3 (30%) cases, while chronic GVHD was documented in 2(20%). Only one case had post-HSCT hypercalcemia. Mixed Chimerism was observed in 8 cases (80%) in the first 100 days, but did not affect transplant outcomes. OS and DFS for the study were 80%. The cause of death was refractory seizures in one patient, while another patient died due to gut GVHD and septicemia. Conclusion: HSCT is the only curative treatment option that improves the clinical manifestation of infantile osteopetrosis. HSCT at an early age in infantile osteopetrosis can lead to a better quality of life in this potentially fatal disease.

Hashim Khan

Poster Presenter: Hashim Khan

Thumbnail for High Specificity but Limited Sensitivity: Is The Khorana Score Sufficient as a Stand-Alone tool to guide Thromboprophylaxis in Contemporary Oncological Practice

CT - 660

High Specificity but Limited Sensitivity: Is The Khorana Score Sufficient as a Stand-Alone tool to guide Thromboprophylaxis in Contemporary Oncological Practice

Manpreet Saini

Poster Presenter: Manpreet Saini

Thumbnail for High-Dose Methotrexate (HDMTX) Protocol Adherence: A Quality Improvement Study at a Tertiary Cancer Center in Pakistan

ALL - 606

High-Dose Methotrexate (HDMTX) Protocol Adherence: A Quality Improvement Study at a Tertiary Cancer Center in Pakistan

Muhammad Sher Ali

Poster Presenter: Muhammad Sher Ali

Thumbnail for Higher ASXL1 Expression Is Associated With Improved Overall Survival in TP53-Mutated Acute Myeloid Leukemia

AML - 1534

Higher ASXL1 Expression Is Associated With Improved Overall Survival in TP53-Mutated Acute Myeloid Leukemia

Max Bustillo

Poster Presenter: Max Bustillo

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors